Goldman Sachs’s Dyne Therapeutics DYN Stock Holding History
Bought
Maintained
Sold
Other funds holding DYN
Goldman Sachs's DYN Position: Q3 2026 in Review
Goldman Sachs reduced its Dyne Therapeutics (DYN) stake by 4.3% in Q3 2026, selling an estimated $2.15M and leaving 2,063,541 shares worth $33.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2087.
Goldman Sachs first reported a position in DYN in Q3 2020 and has held it in 25 quarters since. The position peaked at $74M in Q2 2024. 269 funds tracked by Wall St. Rank hold DYN as of Q3 2026.
- Goldman Sachs held 2,063,541 shares of Dyne Therapeutics worth $33.2M as of Q3 2026.
- Goldman Sachs sold 93,654 Dyne Therapeutics shares in Q3 2026, an estimated $2.15M.
- Dyne Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #2087 holding.
- Goldman Sachs first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 25 quarters since.
- Goldman Sachs's Dyne Therapeutics position peaked at $74M in Q2 2024.
- 269 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.